The problem with repurposing: Is there really an alternative to Big Pharma for developing new drugs for multiple sclerosis?

Multiple Sclerosis and Related Disorders

Volumn 4, Issue 1, 2015, Pages 3-5

  Giovannoni, Gavin ^a   Baker, David ^a   Schmierer, Klaus ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Caldribine; Drug development; Multiple sclerosis; Pharmaceutical industry; Simvastatin

Indexed keywords

ARTICLE; CLINICAL STUDY; COST BENEFIT ANALYSIS; DRUG APPROVAL; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG INDICATION; DRUG INDUSTRY; DRUG RESEARCH; DRUG SAFETY; HUMAN; INCOME; INVESTMENT; MULTIPLE SCLEROSIS; PATENT; PRESCRIPTION; STRATEGIC PLANNING; ADOLESCENT; CHILD; DRUG REPOSITIONING; ECONOMICS; PRESCHOOL CHILD; PROCEDURES; TRENDS;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DRUG INDUSTRY; DRUG REPOSITIONING; HUMANS; MULTIPLE SCLEROSIS;

EID: 84920674917     PISSN: 22110348     EISSN: 22110356     Source Type: Journal    
DOI: 10.1016/j.msard.2014.11.005     Document Type: Article

References (11)

1. Carroll J. Neuroscience groups alarmed as pharma bolts brain drug R&D, ?http://www.fiercebiotech.com/story/neuroscience-groups-alarmed-pharma-bolts-brain-drug-rd/2011-03-28?; 2011 [accessed 17.08.13].
2. J. Chataway, N. Schuerer, A. Alsanousi, D. Chan, D. MacManus, and K. Hunter Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial Lancet 2014
3. Gill D. TransCelerate Biopharma, ?http://transceleratebiopharmainc.com/?; 2012 [accessed 17.08.13].
4. A Jones, and A Duncan Hypothecated taxes and NHS funding J Health Serv Res Policy 3 4 1998 193 194
5. Kesselheim AS. Innovation and the Orphan Drug Act, 1983-2009: Regulatory and clinical characteristics of approved orphan drugs, ?http://www.ncbi.nlm.nih.gov/books/NBK56187/?; 2010 [accessed 17.08.13].
6. T.P. Leist, G. Comi, B.A. Cree, P.K. Coyle, M.S. Freedman, and H.P. Hartung Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial Lancet Neurol 13 3 2014 257 267
7. Anon. Medicine Io. Partnerships and Alternative Business Models: Venture Philanthropy and Orphan Product Development Models, NCBI Bookshelf. 2010.
8. Merck-Serono. Merck: Update on current regulatory development of cladribine tablets, ?http://www.merck.de/de/presse/extNewsDetail.html?newsId=75FEE81CEEA0EE7FC12578B60073A148&newsType=1?; 2011 [accessed 17.08.13].
9. S Morgan, P Grootendorst, J Lexchin, C Cunningham, and D Greyson The cost of drug development: a systematic review Health Policy 100 1 2011 4 17
10. B Munos Lessons from 60 years of pharmaceutical innovation Nat Rev Drug Discov 8 12 2009 959 968
11. Trust W. 0512-5a: Repurposing of medicines and medical devices, ?http://www.wellcome.ac.uk/funding/technology-transfer/awards/health-innovation-challenge-fund/index.htm?; 2013 [accessed 17.08.13].